Trianglemirvetuximab soravtansine (MIRV;… (NCT04606914)
mirvetuximab soravtansine (MIRV; IMGN853) trial for Ovarian Cancer (NCT04606914). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with untreated stage III–IV high-grade serous ovarian, fallopian-tube, or peritoneal cancer suitable for chemotherapy before surgery. Study treatment requires strong folate-receptor-alpha staining in more than seventy-five percent of tumor cells.
The idea: mirvetuximab delivers a cell-division-blocking payload to receptor-bearing cells. Treatment starts with carboplatin alone, then three carboplatin/mirvetuximab cycles before surgery if eligible, followed by three more combination cycles. Infusions occur every three weeks. Researchers assess feasibility and cancer response.
This phase 2 study plans 70 patients. Rebecca Arend leads at UAB, Birmingham; nine US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.